Arbutus Biopharma Corp (NASDAQ:ABUS) – Leerink Swann issued their Q1 2017 earnings per share (EPS) estimates for shares of Arbutus Biopharma Corp in a note issued to investors on Wednesday, Zacks Investment Research reports. Leerink Swann analyst M. Schmidt expects that the biopharmaceutical company will post earnings per share of ($0.38) for the quarter. Leerink Swann also issued estimates for Arbutus Biopharma Corp’s Q2 2017 earnings at ($0.40) EPS.
A number of other brokerages have also recently issued reports on ABUS. Zacks Investment Research upgraded Arbutus Biopharma Corp from a “sell” rating to a “hold” rating in a report on Friday, February 17th. Wedbush reiterated an “outperform” rating and set a $10.00 price target (up previously from $9.00) on shares of Arbutus Biopharma Corp in a report on Wednesday, March 22nd. Bloom Burton upgraded Arbutus Biopharma Corp from an “accumulate” rating to a “buy” rating in a report on Monday, January 9th. Finally, Chardan Capital upgraded Arbutus Biopharma Corp from a “neutral” rating to a “buy” rating and lifted their price target for the company from $3.00 to $6.00 in a report on Tuesday, April 4th. Two analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. Arbutus Biopharma Corp has a consensus rating of “Buy” and an average price target of $6.25.
Arbutus Biopharma Corp (NASDAQ:ABUS) traded up 0.758% during mid-day trading on Thursday, reaching $3.325. The company’s stock had a trading volume of 211,353 shares. Arbutus Biopharma Corp has a 1-year low of $2.35 and a 1-year high of $5.48. The firm has a 50 day moving average price of $3.08 and a 200-day moving average price of $2.88. The company’s market capitalization is $182.95 million.
Hedge funds have recently added to or reduced their stakes in the stock. Ladenburg Thalmann Financial Services Inc. boosted its stake in Arbutus Biopharma Corp by 1,058,889.0% in the fourth quarter. Ladenburg Thalmann Financial Services Inc. now owns 5,294,945 shares of the biopharmaceutical company’s stock worth $12,972,000 after buying an additional 5,294,445 shares during the last quarter. Armistice Capital LLC boosted its stake in Arbutus Biopharma Corp by 38.6% in the fourth quarter. Armistice Capital LLC now owns 1,940,000 shares of the biopharmaceutical company’s stock worth $4,753,000 after buying an additional 540,000 shares during the last quarter. Bank of Montreal Can boosted its stake in Arbutus Biopharma Corp by 6.3% in the third quarter. Bank of Montreal Can now owns 861,553 shares of the biopharmaceutical company’s stock worth $2,964,000 after buying an additional 50,768 shares during the last quarter. Baker BROS. Advisors LP purchased a new stake in Arbutus Biopharma Corp during the third quarter worth about $621,000. Finally, Oxford Asset Management purchased a new stake in Arbutus Biopharma Corp during the fourth quarter worth about $392,000. 61.24% of the stock is owned by hedge funds and other institutional investors.
About Arbutus Biopharma Corp
Arbutus Biopharma Corporation, formerly Tekmira Pharmaceuticals Corporation, is a therapeutic solutions company. The Company is engaged in discovering, developing and commercializing a cure for patients suffering from chronic hepatitis B infection (HBV), a disease of the liver caused by the hepatitis B virus (HBV).
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Arbutus Biopharma Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arbutus Biopharma Corp and related companies with MarketBeat.com's FREE daily email newsletter.